Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Cash Flow: 2015-2024

Historic Net Cash Flow for Apellis Pharmaceuticals (APLS) over the last 10 years, with Dec 2024 value amounting to $61.0 million.

  • Apellis Pharmaceuticals' Net Cash Flow rose 197.81% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.3 million, marking a year-over-year increase of 246.50%. This contributed to the annual value of $61.0 million for FY2024, which is 130.35% up from last year.
  • Apellis Pharmaceuticals' Net Cash Flow amounted to $61.0 million in FY2024, which was up 130.35% from -$200.9 million recorded in FY2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Net Cash Flow peaked at $214.7 million during FY2020, and registered a low of -$200.9 million during FY2023.
  • Moreover, its 3-year median value for Net Cash Flow was -$88.2 million (2022), whereas its average is -$76.0 million.
  • In the last 5 years, Apellis Pharmaceuticals' Net Cash Flow tumbled by 214.95% in 2022 and then surged by 130.35% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Net Cash Flow (Yearly) stood at $214.7 million in 2020, then plummeted by 64.26% to $76.7 million in 2021, then crashed by 214.95% to -$88.2 million in 2022, then plummeted by 127.81% to -$200.9 million in 2023, then skyrocketed by 130.35% to $61.0 million in 2024.